Advertisement

Detection of Tetrahydroisoquinoline, a Parkinsonism-Related Compound, in Parkinsonian Brains and Foods by Gas Chromatography-Mass Spectrometry

  • Toshimitsu Niwa
  • Hideo Yoshizumi
  • Naohito Takeda
  • Akira Tatematsu
  • Sadao Matsuura
  • Toshiharu Nagatsu
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)

Abstract

After 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was discovered to cause parkinsonism in humans, monkeys, and mice,1–2 Nagatsu et al. screened various compounds structurally similar to MPTP for neurotoxicity by assaying the inhibition of tyrosine hydroxylase activity in tissue slices of striatum in situ, and found that both pyridinium and phenyl rings were essential for the effects and that N-methyl-1,2,3,4-tetrahydroisoquinoline (N-Me-TIQ) and 1,2,3,4-tetrahydroisoquinoline (TIQ) could be candidates of endogenous or environmental factors that cause Parkinson’s disease.3

Keywords

Tyrosine Hydroxylase Normal Human Brain Tyrosine Hydroxylase Activity Parkinsonian Brain Double Focus Mass Spectrometer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219: 979 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    R.S. Burns, C.C. Chiueh, S.P. Markey and M.H. Ebebrt, A primate model of Parkinson’s disease: selective destruction of dopaminergic neurons in the pars compacta of substantia nigra by N-methyl-4-phenyl-1,2,3,6tetrahydropyridine. Proc. Natl. Acad. Sci. USA, 80: 4546 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    T. Nagatsu, and Y. Hirata, Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4-phenylpyridinium ion (REP) and the structually related compounds in vitro and in vivo. Europ. J. Neurol., 26 (Supp1.1): 11 (1986).Google Scholar
  4. 4.
    M. Kohno, S. Ohta, and M. Hirobe, Tetrahydroisoquinoline and 1methyltetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem. Biophys. Res. Commun., 140: 448 (1986).PubMedCrossRefGoogle Scholar
  5. 5.
    T. Niwa, N. Takeda, N. Kaneda, Y. Hashizume, and T. Nagatsu, Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem. Biophys. Res. Commun., 144: 1084 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    T. Niwa, N. Takeda, A. Tatematsu, S. Matsuura, M. Yoshida, and T. Nagatsu, Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. J. Chromatogr., 452: 85 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    T. Nagatsu, and M. Yoshida, A endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci. Lett., 87: 178 (1988).PubMedCrossRefGoogle Scholar
  8. 8.
    Y. Makino, S. Ohta, O. Tachikawa, and M. Hirobe, Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to parkinson’s disease. Life Sci, 43: 373 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Toshimitsu Niwa
    • 1
  • Hideo Yoshizumi
    • 2
  • Naohito Takeda
    • 2
  • Akira Tatematsu
    • 2
  • Sadao Matsuura
    • 3
  • Toshiharu Nagatsu
    • 4
  1. 1.Department of Internal MedicineNagoya University Branch HospitalNagoyaJapan
  2. 2.Faculty of PharmacyMeijo UniversityNagoyaJapan
  3. 3.Department of ChemistryNagoya UniversityNagoyaJapan
  4. 4.Department of BiochemistryNagoya University School of MedicineNagoyaJapan

Personalised recommendations